Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Cuts Target Price to $8
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Cuts Target Price to $8
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $20
Buy Rating for Moleculin Biotech on Promising Annamycin Trials and Undervalued Shares
Analysts' Top Healthcare Picks: Moleculin Biotech (MBRX), MiNK Therapeutics (INKT)
Roth MKM: Maintains Moleculin Biotech (MBRX.US) rating, adjusted from buy to buy rating, target price is $40.00.
Moleculin Biotech Analyst Ratings
Roth MKM Maintains Buy on Moleculin Biotech, Maintains $40 Price Target
Maxim Adjusts Price Target on Moleculin Biotech to $20 From $45, Maintains Buy Rating
Moleculin Biotech Analyst Ratings
Maxim Group Maintains Buy on Moleculin Biotech, Lowers Price Target to $20
HC Wainwright & Co. Initiates Coverage On Moleculin Biotech With Buy Rating, Announces Price Target of $3
Moleculin Biotech Analyst Ratings
Oppenheimer Keeps Their Buy Rating on Moleculin Biotech (MBRX)
Analysts' Top Healthcare Picks: Moleculin Biotech (MBRX), Vir Biotechnology (VIR)
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Moleculin Biotech (MBRX)
Maxim Group Reaffirms Their Buy Rating on Moleculin Biotech (MBRX)
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Phibro Animal Health (PAHC) and Moleculin Biotech (MBRX)
Roth MKM Maintains Buy on Moleculin Biotech, Maintains $16 Price Target
Analysts' Top Healthcare Picks: Moleculin Biotech (MBRX), Biomea Fusion (BMEA)
No Data
No Data